

**Resilia Pharmaceuticals, Inc. Manifests Significant Presence
Among Dermatology Nurse Practitioners
By Attending their NADNP National Specialty Meeting in Florida**

Enhanced Face to Face Contact with Dermatology Specialists is
Top Marketing Priority

<< Clearwater, Florida: October 20, 2021>> Rapidly growing dermatology company, Resilia Pharmaceuticals, Inc. made a major marketing impact with influential Dermatology Nurse Practitioners this week by staffing a commercial display and serving as the sponsor of a major event on their annual meeting agenda.

The National Academy of Dermatology Nurse Practitioners is the organization that grants “board certification” to those Nurse Practitioners who’ve acquired added training in order to become specialists in dermatology.

“It has been a pleasure for Resilia to attend this important live conference and showcase our support for the Dermatology community “in-person”, now that the post-COVID environment has enabled us to have greater levels of face-to-face contact with our prescribers” stated Mike Leone, Chief Operating Officer of the Atlanta-based company. “The Resilia sales force is planning to conduct more “in person” office visits as well.” Leone added.

About Resilia Pharmaceuticals

Resilia Pharmaceuticals, Inc. is a portfolio company of Peak Pharma Commercial Partners, a New York City-based investment fund dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products (www.peakpharmapartners.com). Headquartered in Atlanta, Georgia, Resilia Pharmaceuticals’ product line consists of Recedo® topical gel, the #1 prescribed Rx scar treatment over the past 5 years³; Ecoza® (econazole nitrate) topical foam, 1%; the Neosalus® line, including cream, foam, and lotion formulations; and Neocera®, a version of Neosalus formulated with ceramides; all of which are currently marketed in the US.

Resilia’s [Responsible Pricing Policy](#) enables patients to access Resilia’s proven dermatology products at affordable prices. To learn more about Resilia Pharmaceuticals and its products, please go to www.resiliapharma.com

Media Contact:

Josh Weinstein

jwEinstein Strategic Messaging, Inc.

610-577-5388

jwemc2@mac.com

